REDUCE-IT与STRENGTH结果差异的可能解释:模拟试验设计的队列研究
在Copenhagen General Population Study中模拟REDUCE-IT和STRENGTH纳入标准,分析活性油与对照油对血脂和C反应蛋白的影响。结果显示,两项试验结果差异部分源于对照油(矿物油 vs 玉米油)对血脂和CRP的不同效应,而非活性油(EPA vs EPA+DHA)的差异;REDUCE-IT中未解释的额外13%风险降低可能源于EPA或矿物油的其他效应。
要点
- 对照油(矿物油 vs 玉米油)对血脂和CRP的不同效应部分解释了两试验结果差异。
- 活性油(EPA vs EPA+DHA)的差异不能解释两试验结果的不同。
- REDUCE-IT中约13%的额外风险降低未能被血脂和CRP变化解释。
核心结论
- REDUCE-IT与STRENGTH的对比结果部分可由对照油(矿物油 vs 玉米油)对血脂和CRP的不同效应解释,而非活性油(EPA vs EPA+DHA)的差异。
- REDUCE-IT中未解释的额外13%风险降低可能通过EPA或矿物油的其他效应实现。
研究设计与样本
- 基于Copenhagen General Population Study(106 088人)的队列研究,模拟REDUCE-IT和STRENGTH的设计。
- 模拟REDUCE-IT纳入5684人(ASCVD 852例),中位随访4.9年;模拟STRENGTH纳入6862人(ASCVD 697例),中位随访3.5年。
主要发现
- 模拟REDUCE-IT时,结合活性油组观察到的甘油三酯、LDL-C和CRP变化,估计ASCVD风险比为0.96(95%CI 0.93-0.99);模拟STRENGTH时为0.94(0.91-0.98)。
- 模拟REDUCE-IT时,对照油组相应风险比为1.07(1.04-1.10);模拟STRENGTH时为0.99(0.98-0.99)。
- 活性油 vs 对照油的风险比:模拟REDUCE-IT为0.88(0.84-0.93),实际REDUCE-IT为0.75(0.68-0.83);模拟STRENGTH为0.96(0.93-0.99),实际STRENGTH为0.99(0.90-1.09)。
临床怎么用
- 解读REDUCE-IT与STRENGTH结果差异时,应考虑对照油(矿物油 vs 玉米油)对血脂和CRP的不同影响。
- EPA和矿物油可能通过血脂和CRP之外的其他机制影响ASCVD风险,需进一步研究。
局限性
- 本研究为观察性队列模拟,非随机对照试验,可能存在残余混杂。
- 模拟基于Copenhagen General Population Study人群,外推至其他人群需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: We tested the hypothesis that the contrasting results for the effect of high-dose, purified omega-3 fatty acids on the prevention of atherosclerotic cardiovascular disease (ASCVD) in two randomized trials, Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial (REDUCE-IT) vs. Long-Term Outcomes Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridaemia (STRENGTH), can be explained by differences in the effect of active and comparator oils on lipid traits and C-reactive protein. METHODS AND RESULTS: In the Copenhagen General Population Study (CGPS) with 106 088 individuals, to mimic trial designs we analysed those who met key inclusion criteria in REDUCE-IT (n = 5684; ASCVD = 852) and STRENGTH (n = 6862; ASCVD = 697). Atherosclerotic cardiovascular disease incidence was followed for the median durations of REDUCE-IT and STRENGTH (4.9 and 3.5 years), respectively. When combining changes in plasma triglycerides, low-density lipoprotein cholesterol, and C-reactive protein observed in the active oil groups of the original studies, estimated hazard ratios for ASCVD in the CGPS were 0.96 [95% confidence interval 0.93-0.99] mimicking REDUCE-IT and 0.94 (0.91-0.98) mimicking STRENGTH. In the comparator oil groups, corresponding hazard ratios were 1.07 (1.04-1.10) and 0.99 (0.98-0.99). Combining these results, the active oil vs. comparator oil hazard ratio was 0.88 (0.84-0.93) in the CGPS mimicking REDUCE-IT compared to 0.75 (0.68-0.83) in the REDUCE-IT. The corresponding hazard ratio was 0.96 (0.93-0.99) in the CGPS mimicking STRENGTH compared to 0.99 (0.90-1.09) in STRENGTH. CONCLUSION: The contrasting results of REDUCE-IT vs. STRENGTH can partly be explained by a difference in the effect of comparator oils (mineral vs. corn), but not of active oils [eicosapentaenoic acid (EPA) vs. EPA + docosahexaenoic acid], on lipid traits and C-reactive protein. The unexplained additional 13% risk reduction in REDUCE-IT likely is through other effects of EPA or mineral oil.
引用
- Doi T, Langsted A, Nordestgaard BG, et al. A possible explanation for the contrasting results of REDUCE-IT vs. STRENGTH: cohort study mimicking trial designs. Eur Heart J. 2021. PMID: 34455435. doi:10.1093/eurheartj/ehab555
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。